Trans & Non-binary Reference Intervals While on Hormone Therapy Study
NCT04478760 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250
Last updated 2025-09-03
Summary
This study will find out what the reference intervals are for common blood tests in transgender people taking hormone therapy.
Reference intervals help doctors interpret blood test results. They are expressed as two numbers, and most normal results fall between them. If a results fall outside of them, it may be because of a disease. Some blood tests are also affected by normal difference between people, such as age, sex or ethnicity. For these tests, different reference intervals are given for each group of people. Having accurate reference intervals benefits patients because it allows doctors to identify disease faster.
Transgender people have a gender identity which does not match their sex characteristics at birth. Gender identity is the feeling of being a gender, and sex is the biological aspects of growing up male or female. Transgender people may use hormone therapy to help change their appearance to fit their gender identity. This involves taking either oestrogen or testosterone.
For blood tests which are affected by sex, it is not clear what reference intervals should be used for transgender people who are on hormone therapy. This is because they have a mixture of male and female sex characteristics. Answering this question will allow doctors to identify disease in them faster.
The study will take place at cliniQ, at King's College Hospital, which provides health services to transgender people. It will recruit healthy transgender people who attend the clinic for blood tests to monitor their hormone therapy. Participants will fill out a questionnaire, give a urine sample, then have their appointment as normal. Extra tests will also be performed on their blood sample. The aim is to recruit 240 participants. Participant's tests results will then be used to calculate reference intervals.
The study is funded by Viapath Group LLP.
Conditions
- Transgender Persons
- Hormone Replacement Therapy
- Reference Values
Sponsors & Collaborators
-
King's College Hospital NHS Trust
lead OTHER
Principal Investigators
-
Michael Brady, FRCP · King's College Hospital NHS Trust
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-04-13
- Primary Completion
- 2024-05-14
- Completion
- 2024-05-14
Countries
- United Kingdom
Study Locations
More Related Trials
-
Testosterone and Its Metabolites in GID
NCT00146146 ·Status: COMPLETED ·Phase: PHASE3
-
Subcutaneous Testosterone Project
NCT02229617 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trans Health: Evaluation of Markers of Cardio-metabolic Health and Well-being in Transgender Youth
NCT02550431 ·Status: COMPLETED
-
Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure
NCT00957034 ·Status: TERMINATED ·Phase: PHASE2
-
Transgender In Transition
NCT04028219 ·Status: RECRUITING
-
Pharmacokinetics, Pharmacodinamic and Safety of Testosterone Gel 1%
NCT02667561 ·Status: WITHDRAWN ·Phase: PHASE1
-
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
NCT04922424 ·Status: WITHDRAWN ·Phase: PHASE1
-
Changes in Energy Expenditure (EE) in Transsexuals Undergoing Hormonal Therapy
NCT06733415 ·Status: ENROLLING_BY_INVITATION
-
Prospective Observational Study and Biobank CKIO
NCT04440722 ·Status: SUSPENDED
-
Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans
NCT05442463 ·Status: RECRUITING
-
Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen
NCT04534881 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Tolerability of MK0773 in Healthy Older Men (0773-004)
NCT01017458 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population
NCT06247267 ·Status: RECRUITING
-
Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version
NCT07092527 ·Status: RECRUITING ·Phase: PHASE4
-
Transgender Men, Non-binary Persons and Testosterone Treatment BODY IDENTITY CLINIC
NCT04254354 ·Status: RECRUITING
-
Oral T7 Oral Testosterone in Man
NCT00842751 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men with Erythrocytosis
NCT05487794 ·Status: COMPLETED ·Phase: NA
-
GEnder Dysphoria Treatment in Sweden
NCT02518009 ·Status: COMPLETED
-
Cardiometabolic Health in Transgender Males
NCT04977765 ·Status: ACTIVE_NOT_RECRUITING
-
Pubertal Induction in Individuals With Hypogonadism
NCT02871986 ·Status: UNKNOWN
-
Efficacy, Pharmacokinetics and Safety of Testosterone
NCT01370369 ·Status: COMPLETED ·Phase: PHASE2
-
The Testosterone Trials in Older Men
NCT00799617 ·Status: COMPLETED ·Phase: PHASE3
-
Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men
NCT00431197 ·Status: COMPLETED ·Phase: PHASE1
-
Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity
NCT04708431 ·Status: RECRUITING
-
Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
NCT02233751 ·Status: COMPLETED ·Phase: PHASE1